×
QQQ   299.33 (+2.77%)
AAPL   143.78 (+2.32%)
MSFT   265.90 (+1.29%)
FB   191.63 (+4.24%)
GOOGL   2,155.85 (+1.88%)
AMZN   2,221.55 (+4.03%)
TSLA   707.73 (+7.43%)
NVDA   178.51 (+5.16%)
BABA   94.48 (+14.79%)
NIO   16.03 (+9.49%)
AMD   98.75 (+6.58%)
CGC   5.55 (+10.34%)
MU   70.60 (+4.02%)
T   21.32 (+0.09%)
GE   77.01 (+3.33%)
F   13.12 (+3.23%)
DIS   105.61 (+2.28%)
AMC   12.23 (+2.95%)
PFE   53.99 (+0.52%)
PYPL   80.42 (+0.37%)
NFLX   191.40 (+1.90%)
QQQ   299.33 (+2.77%)
AAPL   143.78 (+2.32%)
MSFT   265.90 (+1.29%)
FB   191.63 (+4.24%)
GOOGL   2,155.85 (+1.88%)
AMZN   2,221.55 (+4.03%)
TSLA   707.73 (+7.43%)
NVDA   178.51 (+5.16%)
BABA   94.48 (+14.79%)
NIO   16.03 (+9.49%)
AMD   98.75 (+6.58%)
CGC   5.55 (+10.34%)
MU   70.60 (+4.02%)
T   21.32 (+0.09%)
GE   77.01 (+3.33%)
F   13.12 (+3.23%)
DIS   105.61 (+2.28%)
AMC   12.23 (+2.95%)
PFE   53.99 (+0.52%)
PYPL   80.42 (+0.37%)
NFLX   191.40 (+1.90%)
QQQ   299.33 (+2.77%)
AAPL   143.78 (+2.32%)
MSFT   265.90 (+1.29%)
FB   191.63 (+4.24%)
GOOGL   2,155.85 (+1.88%)
AMZN   2,221.55 (+4.03%)
TSLA   707.73 (+7.43%)
NVDA   178.51 (+5.16%)
BABA   94.48 (+14.79%)
NIO   16.03 (+9.49%)
AMD   98.75 (+6.58%)
CGC   5.55 (+10.34%)
MU   70.60 (+4.02%)
T   21.32 (+0.09%)
GE   77.01 (+3.33%)
F   13.12 (+3.23%)
DIS   105.61 (+2.28%)
AMC   12.23 (+2.95%)
PFE   53.99 (+0.52%)
PYPL   80.42 (+0.37%)
NFLX   191.40 (+1.90%)
QQQ   299.33 (+2.77%)
AAPL   143.78 (+2.32%)
MSFT   265.90 (+1.29%)
FB   191.63 (+4.24%)
GOOGL   2,155.85 (+1.88%)
AMZN   2,221.55 (+4.03%)
TSLA   707.73 (+7.43%)
NVDA   178.51 (+5.16%)
BABA   94.48 (+14.79%)
NIO   16.03 (+9.49%)
AMD   98.75 (+6.58%)
CGC   5.55 (+10.34%)
MU   70.60 (+4.02%)
T   21.32 (+0.09%)
GE   77.01 (+3.33%)
F   13.12 (+3.23%)
DIS   105.61 (+2.28%)
AMC   12.23 (+2.95%)
PFE   53.99 (+0.52%)
PYPL   80.42 (+0.37%)
NFLX   191.40 (+1.90%)
NASDAQ:EDSA

Edesa Biotech (EDSA) Stock Forecast, Price & News

$1.81
+0.07 (+4.02%)
(As of 05/26/2022 04:00 PM ET)
Add
Compare
Today's Range
$1.70
$1.86
50-Day Range
$1.74
$4.01
52-Week Range
$1.70
$12.00
Volume
60,209 shs
Average Volume
81,673 shs
Market Capitalization
$27.99 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.83
30 days | 90 days | 365 days | Advanced Chart
Receive EDSA News and Ratings via Email

Sign-up to receive the latest news and ratings for Edesa Biotech and its competitors with MarketBeat's FREE daily newsletter.

Edesa Biotech logo

About Edesa Biotech

Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EDSA
Employees
16
Year Founded
N/A

Sales & Book Value

Annual Sales
$330 thousand
Book Value
$1.10 per share

Profitability

Net Income
$-13.34 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
8,550,000
Market Cap
$27.99 million
Optionable
Not Optionable

Company Calendar

Last Earnings
5/13/2022
Today
5/26/2022
Next Earnings (Estimated)
8/12/2022
Fiscal Year End
9/30/2022

MarketRank

Overall MarketRank

2.45 out of 5 stars

Medical Sector

174th out of 1,424 stocks

Pharmaceutical Preparations Industry

68th out of 681 stocks

Analyst Opinion: 3.5Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -













Edesa Biotech (NASDAQ:EDSA) Frequently Asked Questions

Is Edesa Biotech a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Edesa Biotech in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Edesa Biotech stock.
View analyst ratings for Edesa Biotech
or view top-rated stocks.

When is Edesa Biotech's next earnings date?

Edesa Biotech is scheduled to release its next quarterly earnings announcement on Friday, August 12th 2022.
View our earnings forecast for Edesa Biotech
.

How were Edesa Biotech's earnings last quarter?

Edesa Biotech, Inc. (NASDAQ:EDSA) announced its earnings results on Friday, May, 13th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.37) by $0.04.
View Edesa Biotech's earnings history
.

What price target have analysts set for EDSA?

1 equities research analysts have issued 1-year price objectives for Edesa Biotech's shares. Their forecasts range from $16.00 to $16.00. On average, they expect Edesa Biotech's share price to reach $16.00 in the next year. This suggests a possible upside of 784.0% from the stock's current price.
View analysts' price targets for Edesa Biotech
or view top-rated stocks among Wall Street analysts.

Who are Edesa Biotech's key executives?
Edesa Biotech's management team includes the following people:
  • Dr. Pardeep Nijhawan FRCPC, M.D., CEO, Company Sec. & Director (Age 51, Pay $498.77k)
  • Dr. Michael J. Brooks M.B.A., Ph.D., Pres (Age 44, Pay $446.09k)
  • Ms. Kathi Niffenegger CPA, CPA, Chief Financial Officer (Age 65, Pay $435.92k)
  • Mr. Gary Koppenjan, VP of Investor Relations & Communications
  • Mr. Rajan Puri, Sr. VP of Manufacturing
What other stocks do shareholders of Edesa Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Edesa Biotech investors own include Pfizer (PFE), AbbVie (ABBV), VBI Vaccines (VBIV), Vaxart (VXRT), Exxon Mobil (XOM), Anavex Life Sciences (AVXL), Occidental Petroleum (OXY), Sorrento Therapeutics (SRNE), AT&T (T) and Amarin (AMRN).

What is Edesa Biotech's stock symbol?

Edesa Biotech trades on the NASDAQ under the ticker symbol "EDSA."

Who are Edesa Biotech's major shareholders?

Edesa Biotech's stock is owned by a number of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (0.59%) and National Bank of Canada FI (0.07%). Company insiders that own Edesa Biotech stock include Frank R Oakes, Michael J Brooks and Pardeep Nijhawan.
View institutional ownership trends for Edesa Biotech
.

Which institutional investors are buying Edesa Biotech stock?

EDSA stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, and National Bank of Canada FI. Company insiders that have bought Edesa Biotech stock in the last two years include Michael J Brooks, and Pardeep Nijhawan.
View insider buying and selling activity for Edesa Biotech
or or view top insider-buying stocks.

How do I buy shares of Edesa Biotech?

Shares of EDSA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Edesa Biotech's stock price today?

One share of EDSA stock can currently be purchased for approximately $1.81.

How much money does Edesa Biotech make?

Edesa Biotech has a market capitalization of $27.99 million and generates $330 thousand in revenue each year. The company earns $-13.34 million in net income (profit) each year or ($1.290010) on an earnings per share basis.

How many employees does Edesa Biotech have?

Edesa Biotech employs 16 workers across the globe.

What is Edesa Biotech's official website?

The official website for Edesa Biotech is www.edesabiotech.com.

How can I contact Edesa Biotech?

Edesa Biotech's mailing address is 100 SPY COURT, MARKHAM A6, L3R 5H6. The company can be reached via phone at (289) 800-9600, via email at investors[email protected], or via fax at 805-488-2889.

This page was last updated on 5/26/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.